ALGS
NASDAQ · Biotechnology
Aligos Therapeutics Inc
$6.44
+0.41 (+6.80%)
Open$6.11
Previous Close$6.03
Day High$6.57
Day Low$5.86
52W High$13.69
52W Low$5.12
Volume—
Avg Volume153.8K
Market Cap41.40M
P/E Ratio—
EPS$-1.54
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-3.9% upside
Current
$6.44
$6.44
Target
$6.19
$6.19
$4.22
$6.19 avg
$8.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.42M | 2.63M | 10.09M |
| Net Income | -15,732,570 | -26,240,387 | -1,613,644 |
| Profit Margin | -1,106.7% | -1,051.4% | -16.0% |
| EBITDA | -16,330,376 | -28,750,661 | -2,029,249 |
| Free Cash Flow | — | — | -1,586,727 |
| Rev Growth | -46.0% | -46.0% | -9.4% |
| Debt/Equity | 0.00 | 0.00 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |